Advertisement

Aging Clinical and Experimental Research

, Volume 31, Issue 2, pp 287–289 | Cite as

Benzodiazepine ingestion as a way to die by suicide and related safety: the case of an elderly patient

  • Laura Cremaschi
  • Benedetta Grancini
  • Vera De Carlo
  • Sara Pozzoli
  • A. Carlo Altamura
  • Bernardo Dell’OssoEmail author
Case Report

Abstract

Benzodiazepines (BDZs) are widespread psychotropic compounds, often prescribed as first-line symptomatic option by general practitioners in patients with different psychiatric disorders. Sometimes, however, they contribute to delay the administration of the first appropriate psychopharmacological treatment, thus leading to a longer duration of untreated illness in patients with depressive and anxiety disorders. The well-established pros of BDZs use in clinical practice include efficacy, rapidity of action, versatility, and safety. Among the cons, BDZs can provoke cognitive side-effects, asthenia, and misuse/abuse. Although their overall safety has been traditionally viewed as one of their greatest strengths, BDZs massive ingestion for suicidal purposes may pose, in some cases, serious life-threatening conditions, as described in the present case report. Hence, particular attention needs to be paid in prescribing these compounds to special populations, such as elderly patients. Among these, their prescription should be limited to the short-term and particularly monitored in case of risk factors, as they may be unsafe in case of overdose.

Keywords

Benzodiazepines Suicide Elderly Hypnotics 

Notes

Compliance with ethical standards

Conflict of interest

We wish to confirm that there are no conflicts of interest associated with the present publication and there has been no significant financial support for this work that could have influenced its outcome.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from the patient.

References

  1. 1.
    Dell’Osso B, Lader M (2013) Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry 28:7–20.  https://doi.org/10.1016/j.eurpsy.2011.11.003 CrossRefGoogle Scholar
  2. 2.
    Grancini B, De Carlo V, Palazzo M et al (2018) Does initial use of benzodiazepines delay an adequate pharmacological treatment? A multicentre analysis in patients with psychotic and affective disorders. Int Clin Psychopharmacol.  https://doi.org/10.1097/YIC.0000000000000210 Google Scholar
  3. 3.
    Starcevic V (2014) The reappraisal of benzodiazepines in the treatment of anxiety and related disorders. Expert Rev Neurother 14:1275–1286.  https://doi.org/10.1586/14737175.2014.963057 CrossRefGoogle Scholar
  4. 4.
    Pompili M, Serafini G, Innamorati M et al (2010) Antidepressants and suicide risk: a comprehensive overview. Pharmaceuticals 3:2861–2883.  https://doi.org/10.3390/ph3092861 CrossRefGoogle Scholar
  5. 5.
    McCall WV, Benca RM, Rosenquist PB et al (2017) Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. Am J Psychiatry 174:18–25.  https://doi.org/10.1176/appi.ajp.2016.16030336 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Laura Cremaschi
    • 1
  • Benedetta Grancini
    • 1
  • Vera De Carlo
    • 1
  • Sara Pozzoli
    • 1
  • A. Carlo Altamura
    • 1
  • Bernardo Dell’Osso
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Mental Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoUniversity of MilanMilanItaly
  2. 2.Department of Psychiatry and Behavioural SciencesBipolar Disorders Clinic, Stanford UniversityStanfordUSA
  3. 3.CRC “Aldo Ravelli” for Neurotechnology and Experimental Brain TherapeuticsUniversity of MilanMilanItaly

Personalised recommendations